MedTrace Logo

Named Patient Program for Olverembatinib (HQP1351)

NCT05594758 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-02-07

No results posted yet for this study

Summary

This program will allow eligible patients access to Ascentage Pharma's novel drug candidate Olverembatinib (approved in China) on a named patient basis in over 100 countries ( with the exception of the USA and China) and regions where the drug is not available.

Interventions

DRUG

Olverembatinib

Oral Olverembatinib

Sponsors & Collaborators

  • Tanner Pharma Group

    collaborator OTHER

  • Ascentage Pharma Group Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05594758 on ClinicalTrials.gov